Breaking News, Collaborations & Alliances

Degron Enters Collaboration & License Agreement with Takeda

Will discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.

Author Image

By: Charlie Sternberg

Associate Editor

Degron Therapeutics, a company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, has entered a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.   The companies will collaborate to utilize Degron’s GlueXplorer platform to identify, validate, and optimize molecular glue degraders for specific therapeutic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters